The immune system plays a crucial role in certain aspects of ALS disease progression. This compound tamps down the immune system by blocking CD40 positive antigen presenting cells from becoming activated macrophage.
Thanks to Ice Bucket Challenge donations, we were able to invest $1.5 million into this program to pay for the manufacturing of 10,000 units of this compound necessary for IND enabling studies and trials through Phase 2B.
A phase IIA trial asks whether Gilenya might have the potential to slow ALS by reducing T cell-mediated inflammation.
Anti-CD40L delays the onset of paralysis and extends the survival of a mouse model of ALS.
Topics in the Pipeline